| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 75.69% | 76.12% | 74.24% | 77.61% | 80.79% | 86.57% | 86.40% | 86.50% | 86.72% | 87.08% | 88.48% | 87.93% |
| Operating Margin | — | — | — | — | 25.87% | 33.84% | 48.98% | 43.77% | 43.54% | 44.99% | 45.44% | 40.94% |
| EBITDA Margin | — | — | — | — | 30.31% | 37.24% | 53.72% | 51.33% | 52.35% | 50.95% | 51.02% | 48.03% |
| Net Margin | 13.07% | 16.87% | 11.81% | 29.95% | 14.17% | 29.76% | 40.96% | 32.93% | 20.69% | 32.34% | 32.95% | 30.25% |
| Current Ratio | 2.68 | 1.35 | 2.00 | 2.99 | 1.83 | 1.84 | 1.72 | 2.32 | 2.34 | 2.55 | 2.60 | 2.11 |
| Quick Ratio | 2.03 | 0.90 | 1.26 | 2.58 | 1.51 | 1.55 | 1.56 | 2.04 | 2.07 | 2.26 | 2.25 | 1.74 |
| Debt / Equity | 0.34 | 0.48 | 0.48 | 0.47 | 0.66 | 0.69 | 0.45 | 0.46 | 0.47 | 0.54 | 0.70 | 0.05 |
| ROE | 7.08% | 9.76% | 7.85% | 22.76% | 14.20% | 37.44% | 44.14% | 34.00% | 20.15% | 30.53% | 37.84% | 27.14% |
| ROA | 4.39% | 5.82% | 4.33% | 12.41% | 6.52% | 16.25% | 21.62% | 17.52% | 10.73% | 16.19% | 18.19% | 20.50% |
| Asset Turnover | 0.34 | 0.34 | 0.37 | 0.41 | 0.46 | 0.55 | 0.53 | 0.53 | 0.52 | 0.50 | 0.55 | 0.68 |
| Book Value / Share | 124.11 | 114.57 | 101.64 | 91.70 | 73.26 | 66.25 | 71.18 | 63.48 | 59.15 | 55.43 | 40.55 | 45.60 |
Biogen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers products such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis; SPINRAZA for spinal muscular atrophy; SKYCLARYS for Friedreich's Ataxia; QALSODY for amyotrophic lateral sclerosis; FUMADERM for plaque psoriasis; BENEPALI, an etanercept biosimilar; and IMRALDI, an adalimumab biosimilar. Biogen Inc. focuses on addressing unmet medical needs in the fields of neurology, including multiple sclerosis, spinal muscular atrophy, and rare diseases like Friedreich's Ataxia and ALS. Its portfolio emphasizes innovative treatments that target the underlying mechanisms of these debilitating conditions, serving patients through specialized healthcare channels worldwide. Founded in 1978 and headquartered in Cambridge, Massachusetts, Biogen Inc. plays a vital role in advancing biopharmaceutical solutions for complex neurological disorders.